These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17317399)

  • 1. Vitreous injections of pegaptanib sodium triggering allergic reactions.
    Steffensmeier AC; Azar AE; Fuller JJ; Muller BA; Russell SR
    Am J Ophthalmol; 2007 Mar; 143(3):512-3. PubMed ID: 17317399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock).
    Limsuwan T; Demoly P
    Med Clin North Am; 2010 Jul; 94(4):691-710, x. PubMed ID: 20609858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
    Williams AJ; Fekrat S
    Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RPE tears after pegaptanib treatment in age-related macular degeneration.
    Chang LK; Flaxel CJ; Lauer AK; Sarraf D
    Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit.
    Foy JW; Rittenhouse K; Modi M; Patel M
    J Ocul Pharmacol Ther; 2007 Oct; 23(5):452-66. PubMed ID: 17900226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA; Hassan TS; Williams GA
    Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
    N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal silicone oil droplets following pegaptanib injection.
    Kocabora MS; Ozbilen KT; Serefoglu K
    Acta Ophthalmol; 2010 Mar; 88(2):e44-5. PubMed ID: 18976315
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M; Feucht N; Huebner M; Lohmann C
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.
    Liggett PE; Colina J; Chaudhry NA; Tom D; Haffner G
    Am J Ophthalmol; 2006 Dec; 142(6):1072-4. PubMed ID: 17157599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration.
    Emerson GG; Flaxel CJ; Lauer AK; Stout JT; Emerson MV; Nolte S; Wilson DJ; Klein ML
    Retina; 2007; 27(6):724-9. PubMed ID: 17621181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
    Ju M; Mailhos C; Bradley J; Dowie T; Ganley M; Cook G; Calias P; Lange N; Adamis AP; Shima DT; Robinson GS
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal pigment epithelial tear following intravitreal pegaptanib sodium.
    Dhalla MS; Blinder KJ; Tewari A; Hariprasad SM; Apte RS
    Am J Ophthalmol; 2006 Apr; 141(4):752-4. PubMed ID: 16564819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
    Frenkel RE; Mani L; Toler AR; Frenkel MP
    Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
    Meyer CH; Eter N
    Am J Ophthalmol; 2008 Feb; 145(2):386-7. PubMed ID: 18222195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.